Select Publications
Conference Abstracts
2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
,2019, 'Abstract 4820: Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', in Experimental and Molecular Therapeutics, American Association for Cancer Research, pp. 4820 - 4820, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-4820
,2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-3839
,2019, 'Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-4820
,2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741
,2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
,2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137
,2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138
,2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier BV, Vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
,2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
,2017, 'Therapeutic targeting of a9b1 and a4b1 integrins for chemosensitization of drug resistant acute leukaemia', in Experimental Hematology, Elsevier BV, Vol. 53, pp. S75 - S75, http://dx.doi.org/10.1016/j.exphem.2017.06.158
,2016, 'Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 128, presented at 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), CA, San Diego, 03 December 2016 - 06 December 2016, http://dx.doi.org/10.1182/blood.V128.22.1740.1740
,2015, 'Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, Vol. 126, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.3766.3766
,2015, 'Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, Vol. 126, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368021800016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'A REVIEW OF NEW AGENTS TESTED BY THE PEDIATRIC PRECLINICAL TESTING PROGRAM AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, Vol. 62, pp. S211 - S211, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361247200258&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-3276
,2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611
,2014, 'Identifying the Factors Modulating the Efficacy of CAR-T Cell Therapy', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242705041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'IDENTIFYING THE FACTORS MODULATING THE EFFICACY OF CAR-T CELL THERAPY', in CYTOTHERAPY, ELSEVIER SCI LTD, Vol. 16, pp. S7 - S7, http://dx.doi.org/10.1016/j.jcyt.2014.01.015
,2013, 'Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, Vol. 12, http://dx.doi.org/10.1158/1535-7163.TARG-13-C206
,2011, 'In vivo exposure of infant leukemia to the BH3-mimetic ABT-263 selects for a cell death-resistant phenotype', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-23
,2011, 'Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5358
,2009, 'Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A.', in J Clin Oncol, United States, Vol. 27, pp. 10015, United States, http://www.ncbi.nlm.nih.gov/pubmed/27962529
,2006, 'Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 81 - 81, http://dx.doi.org/10.1016/S1359-6349(06)70257-9
,Preprints
2024, Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML, http://dx.doi.org/10.1101/2024.04.17.589858
,2024, Targeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia, http://dx.doi.org/10.21203/rs.3.rs-4608404/v1
,2023, Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas, http://dx.doi.org/10.1101/2023.07.19.548825
,2023, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1
,2022, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687
,2019, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455
,Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design, http://dx.doi.org/10.2139/ssrn.3377367
,The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care, http://dx.doi.org/10.2139/ssrn.3260779
,Other
2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v3
,2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213.v1
,2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210.v1
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210
,2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207.v1
,2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207
,2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204.v1
,2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v2
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251.v1
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v1
,